PDCD1 and melanoma: In contrast, miR-4649-3p and miR-615-3p overexpression was observed in stage IV melanoma patients who progressed after anti-CTLA-4 (Ipilimumab), anti-PD-1 (Nivolumab or Pembrolizumab), or the combination of Ipilimumab and Nivolumab [42].